EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, today announced that Daniel Wiegand, CEO, and Jonathan Rittichier, CSO, both co-founders of the company, will be participating in the 19th annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain, beginning October 22nd. The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board. Dr. Watts, who was also a member of the Board of Directors of the Oligonucleotide Therapeutics Society (OTS) from 2015 to 2021, is a highly regarded scientific investigator in the oligonucleotide field. His expertise will provide meaningful contributions as EnPlusOne continues to develop and scale its proprietary enzymatic RNA (ezRNA™) synthesis platform enabling next-generation solutions for emerging RNA therapeutics.
Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and EnPlusOne Biosciences (EnPlusOne Bio) announced that the startup company has signed a worldwide, exclusive licensing agreement with Harvard’s Office of Technology Development (OTD) that grants EnPlusOne Bio the rights to commercialize a novel, controlled enzymatic RNA oligonucleotide synthesis technology. The “ezRNA” platform technology was invented and advanced by Wyss Core Faculty member George Church, Ph.D. and an expert team of biologists, chemists, and life science entrepreneurs at the Wyss Institute, and supported and funded by Northpond Labs, the research and development-focused affiliate of Northpond Ventures, as the inaugural project of the Wyss Institute Northpond Labs alliance.
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today formally launched with $12 million in seed financing. The round was led by Northpond Ventures with participation from Breakout Ventures, Coatue, and angel investors. The financing will support continued development and scaling of the company’s proprietary ezRNA™ synthesis platform in line with the company’s mission to enable next-generation solutions for emerging RNA therapeutics.
